The Saudi Food and Drug Authority (SFDA), through its educational arm, the Food and Drug Academy, and in cooperation with the SFDA Drug Sector, conducted a training program for specialists from the Gulf Health Council (GHC). The program was held on December 3–4 at the SFDA headquarters in Riyadh.

Titled “Evaluation of Clinical Studies to Support the Registration of Vaccines and Biosimilars, and New Registration of Biologics and Innovative Products,” the program aimed to demonstrate the rigorous, standardized process for evaluating clinical studies used to support the registration of these complex medicines.

The training focused specifically on the mechanism for conducting a sound evaluation of these studies according to established clinical standards and international practices. The curriculum also included a definition of various product and vaccine types, their differences, and the corresponding regulatory registration requirements for each category.